NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Lenacapavir for prevention of HIV-1 in people 16 years and over ID6495

Provisional Stakeholder List

Provisional consultees	**Provisional commentators (no right to submit or appeal)**
Company • Gilead (lenacapavir) Community organisations • African Advocacy Foundation • African Health Policy Network • Aymara Social Enterprise • Black Health Agency for Equality • George House Trust • HIV-i-Base • LGBT Foundation • LGBT Hero • Love Tank • National AIDS Trust • NAZ Project • Positively UK • Sophia Forum • South Asian Health Foundation • Specialised Healthcare Alliance • Terrence Higgins Trust • UK-CAB Healthcare professional groups • Association for Clinical Biochemistry and Laboratory Medicine – Microbiology Section • British Association for Psychopharmacology • British Association for Sexual Health and HIV • British Geriatrics Society • British HIV Association • British Infection Association • Children's HIV Association (CHIVA) • English HIV and Sexual Health Commissioners Group (EHSHSG)	General • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Haemophilia Wales • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Confederation • Scottish Medicines Consortium • Welsh Government • NHS Wales Joint Commissioning Committee Possible comparator companies • Advanz Pharma (emtricitabine/tenofovir disoproxil fumarate) • Amarox Ltd (tenofovir disoproxil fumarate, emtricitabine/tenofovir disoproxil fumarate) • Aurobindo Pharma - Milpharm Ltd. (tenofovir disoproxil fumarate, emtricitabine/tenofovir disoproxil fumarate) • Dr Reddy's Laboratories (tenofovir disoproxil succinate, emtricitabine/tenofovir disoproxil succinate)

Provisional consultees	**Provisional commentators (no right to submit or appeal)**
• HIVPA • Infection Prevention Society • Microbiology Society • National HIV Nurses Association • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal College of Psychiatrists • Royal Society of Medicine • UK Clinical Pharmacy Association • UK Clinical Virology Network <u>Others</u> • Association of Directors of Public Health (ADPH) • Department of Health and Social Care • NHS England	• Gilead ([emtricitabine/tenofovir alafenamide fumarate], emtricitabine/tenofovir disoproxil fumarate, tenofovir disoproxil fumarate, emtricitabine) • Lupin Healthcare UK Ltd (emtricitabine/tenofovir disoproxil phosphate) • Mylan (tenofovir disoproxil maleate) • Orion (tenofovir disoproxil fumarate) • Sandoz (tenofovir disoproxil) • Thornton & Ross Ltd (tenofovir disoproxil succinate) • ViiV Healthcare (cabotegravir) <u>Relevant research groups</u> • Cochrane Infectious Diseases Group • Genomics England • MRC Clinical Trials Unit • National Institute for Health Research • UCL Centre for Sexual Health & HIV Research • UK National Screening Committee <u>Associated Public Health groups</u> • Public Health Wales • UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

<u>Consultees</u>

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient/community organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient/community experts.

